Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 13/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197120 | 1.00 | GAA (0.64) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14368075 | 1.00 | GAA (0.64) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14338233 | 1.00 | GAA (0.64) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14393690 | 0.84 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL16901643 | 0.84 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL4649609 | 0.84 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14008046 | 0.84 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14008045 | 0.84 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14393866 | 0.84 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL15883839 | 0.82 | GAA (0.60) | GAAKDM4EALDH1A1AOC3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304071-B2 | Protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304071-B2 | Protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | GAA 4640/4885KDM4E 4090/4885ALDH1A1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.